Literature DB >> 22474251

RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans.

Anja Troeger1, Amy J Johnson, Jenna Wood, William G Blum, Leslie A Andritsos, John C Byrd, David A Williams.   

Abstract

Trafficking of B-cell chronic lymphocytic leukemia (CLL) cells to the bone marrow and interaction with supporting stromal cells mediates important survival and proliferation signals. Previous studies have demonstrated that deletion of Rhoh led to a delayed disease onset in a murine model of CLL. Here we assessed the impact of RhoH on homing, migration, and cell-contact dependent interactions of CLL cells. Rhoh(-/-) CLL cells exhibited reduced marrow homing and subsequent engraftment. In vitro migration toward the chemokines CXCL12 and CXCL13 and cell-cell interactions between Rhoh(-/-) CLL cells and the supporting microenvironment was reduced. In the absence of RhoH the distribution of phosphorylated focal adhesion kinase, a protein known to coordinate activation of the Rho GTPases RhoA and Rac, appeared less polarized in chemokine-stimulated Rhoh(-/-) CLL cells, and activation and localization of RhoA and Rac was dysregulated leading to defective integrin function. These findings in the Rhoh(-/-) CLL cells were subsequently demonstrated to closely resemble changes in GTPase activation observed in human CLL samples after in vitro and in vivo treatment with lenalidomide, an agent with known influence on microenvironment protection, and suggest that RhoH plays a critical role in prosurvival CLL cell-cell and cell-microenvironment interactions with this agent.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22474251      PMCID: PMC3367874          DOI: 10.1182/blood-2011-12-395939

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  55 in total

1.  Rho GTPases control migration and polarization of adhesion molecules and cytoskeletal ERM components in T lymphocytes.

Authors:  M A del Pozo; M Vicente-Manzanares; R Tejedor; J M Serrador; F Sánchez-Madrid
Journal:  Eur J Immunol       Date:  1999-11       Impact factor: 5.532

2.  HS1 has a central role in the trafficking and homing of leukemic B cells.

Authors:  Cristina Scielzo; Maria T S Bertilaccio; Giorgia Simonetti; Antonis Dagklis; Elisa ten Hacken; Claudia Fazi; Marta Muzio; Valeria Caiolfa; Daisuke Kitamura; Umberto Restuccia; Angela Bachi; Martina Rocchi; Maurilio Ponzoni; Paolo Ghia; Federico Caligaris-Cappio
Journal:  Blood       Date:  2010-06-08       Impact factor: 22.113

3.  Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.

Authors:  Christine I Chen; P Leif Bergsagel; Harminder Paul; Wei Xu; Anthea Lau; Nimisha Dave; Vishal Kukreti; Ellen Wei; Chungyee Leung-Hagesteijn; Zhi Hua Li; Joseph Brandwein; Mariela Pantoja; James Johnston; Spencer Gibson; Tiffany Hernandez; David Spaner; Suzanne Trudel
Journal:  J Clin Oncol       Date:  2010-12-28       Impact factor: 44.544

4.  Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells.

Authors:  J A Burger; M Burger; T J Kipps
Journal:  Blood       Date:  1999-12-01       Impact factor: 22.113

5.  RhoH plays distinct roles in T-cell migrations induced by different doses of SDF1 alpha.

Authors:  Hong Wang; Xin Zeng; Zhigang Fan; Bing Lim
Journal:  Cell Signal       Date:  2010-02-22       Impact factor: 4.315

6.  Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1).

Authors:  R Möhle; C Failenschmid; F Bautz; L Kanz
Journal:  Leukemia       Date:  1999-12       Impact factor: 11.528

Review 7.  Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.

Authors:  Farrukh T Awan; Amy J Johnson; Rosa Lapalombella; Weihong Hu; Margaret Lucas; Beth Fischer; John C Byrd
Journal:  Leuk Lymphoma       Date:  2010-01

8.  Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

Authors:  Rosa Lapalombella; Leslie Andritsos; Qing Liu; Sarah E May; Rebekah Browning; Lan V Pham; Kristie A Blum; William Blum; Asha Ramanunni; Chelsey A Raymond; Lisa L Smith; Amy Lehman; Xiaokui Mo; David Jarjoura; Ching-Shih Chen; Richard Ford; Christoph Rader; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2009-11-24       Impact factor: 22.113

9.  RhoH regulates subcellular localization of ZAP-70 and Lck in T cell receptor signaling.

Authors:  Hee-Don Chae; Jamie E Siefring; David A Hildeman; Yi Gu; David A Williams
Journal:  PLoS One       Date:  2010-11-12       Impact factor: 3.240

10.  Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance.

Authors:  Antonina V Kurtova; Kumudha Balakrishnan; Rong Chen; Wei Ding; Susanne Schnabl; Maite P Quiroga; Mariela Sivina; William G Wierda; Zeev Estrov; Michael J Keating; Medhat Shehata; Ulrich Jäger; Varsha Gandhi; Neil E Kay; William Plunkett; Jan A Burger
Journal:  Blood       Date:  2009-09-17       Impact factor: 22.113

View more
  21 in total

1.  Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.

Authors:  Stefania Fiorcari; Silvia Martinelli; Jenny Bulgarelli; Valentina Audrito; Patrizia Zucchini; Elisabetta Colaci; Leonardo Potenza; Franco Narni; Mario Luppi; Silvia Deaglio; Roberto Marasca; Rossana Maffei
Journal:  Haematologica       Date:  2014-11-14       Impact factor: 9.941

Review 2.  The tumor microenvironment shapes hallmarks of mature B-cell malignancies.

Authors:  K H Shain; W S Dalton; J Tao
Journal:  Oncogene       Date:  2015-02-02       Impact factor: 9.867

3.  RhoH participates in a multi-protein complex with the zinc finger protein kaiso that regulates both cytoskeletal structures and chemokine-induced T cells.

Authors:  Akihisa Mino; Anja Troeger; Christian Brendel; Alan Cantor; Chad Harris; Marioara F Ciuculescu; David A Williams
Journal:  Small GTPases       Date:  2016-08-31

Review 4.  Hematopoietic-specific Rho GTPases Rac2 and RhoH and human blood disorders.

Authors:  Anja Troeger; David A Williams
Journal:  Exp Cell Res       Date:  2013-07-11       Impact factor: 3.905

5.  Bone marrow fibrosis at diagnosis predicts survival for primary acute myeloid leukemia.

Authors:  Z Wu; R Chen; L Wu; L Zou; F Ding; M Wang; X Liu
Journal:  Clin Transl Oncol       Date:  2017-06-06       Impact factor: 3.405

Review 6.  Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.

Authors:  Elisa Ten Hacken; Jan A Burger
Journal:  Biochim Biophys Acta       Date:  2015-07-17

7.  Chaetoglobosin A preferentially induces apoptosis in chronic lymphocytic leukemia cells by targeting the cytoskeleton.

Authors:  P B Knudsen; B Hanna; S Ohl; L Sellner; T Zenz; H Döhner; S Stilgenbauer; T O Larsen; P Lichter; M Seiffert
Journal:  Leukemia       Date:  2013-11-27       Impact factor: 11.528

Review 8.  Rho GTPases: Regulation and roles in cancer cell biology.

Authors:  Raquel B Haga; Anne J Ridley
Journal:  Small GTPases       Date:  2016-09-14

Review 9.  Differential network analysis in human cancer research.

Authors:  Ryan Gill; Somnath Datta; Susmita Datta
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 10.  Roles of Rho GTPases in leucocyte and leukaemia cell transendothelial migration.

Authors:  Elvira Infante; Anne J Ridley
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-09-23       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.